Sharma, P. & Allison, J. P. Dissecting the mechanisms of immune checkpoint therapy. Nat. Rev. Immunol. 20, 75–76 (2020).
Minn, A. J. & Wherry, E. J. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 165, 272–275 (2016).
Tang, Z. & Veillette, A. Inhibitory immune checkpoints in cancer immunotherapy. Sci. Immunol. 10, eadv6870 (2025).
Wu, N. & Veillette, A. SLAM family receptors in normal immunity and immune pathologies. Curr. Opin. Immunol. 38, 45–51 (2016).
Cannons, J. L., Tangye, S. G. & Schwartzberg, P. L. SLAM family receptors and SAP adaptors in immunity. Annu. Rev. Immunol. 29, 665–705 (2011).
Yigit, B., Wang, N., Herzog, R. W. & Terhorst, C. SLAMF6 in health and disease: implications for therapeutic targeting. Clin. Immunol. 204, 3–13 (2019).
Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840–855 (2019).
Chen, Y. et al. BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection. Nat. Immunol. 22, 996–1007 (2021).
Schenkel, J. M. et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity 54, 2338–2353 (2021).
Gill, A. L. et al. PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors. Sci. Immunol. 8, eadg0539 (2023).
Wang, K. et al. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. Cancer Cell 42, 1582–1597 (2024).
Shen, Y. et al. Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node. Nat. Commun. 16, 3522 (2025).
Chatterjee, M. et al. CD3-T cell receptor co-stimulation through SLAMF3 and SLAMF6 receptors enhances RORγt recruitment to the IL17A promoter in human T lymphocytes. J. Biol. Chem. 287, 38168–38177 (2012).
Chatterjee, M., Kis-Toth, K., Thai, T. H., Terhorst, C. & Tsokos, G. C. SLAMF6-driven co-stimulation of human peripheral T cells is defective in SLE T cells. Autoimmunity 44, 211–218 (2011).
Dragovich, M. A. et al. SLAMF6 clustering is required to augment T cell activation. PLoS ONE 14, e0218109 (2019).
Eisenberg, G. et al. Soluble SLAMF6 receptor induces strong CD8+ T-cell effector function and improves anti-melanoma activity in vivo. Cancer Immunol. Res. 6, 127–138 (2018).
Gartshteyn, Y. et al. SLAMF6 compartmentalization enhances T cell functions. Life Sci. Alliance https://doi.org/10.26508/lsa.202201533 (2023).
Dutta, M. et al. A role for Ly108 in the induction of promyelocytic zinc finger transcription factor in developing thymocytes. J. Immunol. 190, 2121–2128 (2013).
Bisht, A. & Ackroyd, J. Antibodies and methods of use. World patent WO2021001653A1 (2020).
Yigit, B. et al. SLAMF6 as a regulator of exhausted CD8+ T cells in cancer. Cancer Immunol. Res. 7, 1485–1496 (2019).
Howie, D. et al. Cutting edge: the SLAM family receptor Ly108 controls T cell and neutrophil functions. J. Immunol. 174, 5931–5935 (2005).
Dong, Z. & Veillette, A. How do SAP family deficiencies compromise immunity? Trends Immunol. 31, 295–302 (2010).
Hajaj, E. et al. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. elife https://doi.org/10.7554/eLife.52539 (2020).
Wang, N. et al. Slamf6 negatively regulates autoimmunity. Clin. Immunol. 173, 19–26 (2016).
Lu, Y. et al. SLAM receptors foster iNKT cell development by reducing TCR signal strength after positive selection. Nat. Immunol. 20, 447–457 (2019).
Zhong, M. C. & Veillette, A. Control of T lymphocyte signaling by Ly108, a signaling lymphocytic activation molecule family receptor implicated in autoimmunity. J. Biol. Chem. 283, 19255–19264 (2008).
Bygrave, A. E. et al. Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol. 2, E243 (2004).
Wandstrat, A. E. et al. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity 21, 769–780 (2004).
Majeti, R. et al. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 103, 1059–1070 (2000).
Gupta, V. A., Hermiston, M. L., Cassafer, G., Daikh, D. I. & Weiss, A. B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency. J. Exp. Med. 205, 2755–2761 (2008).
Hui, E. Cis interactions of membrane receptors and ligands. Annu. Rev. Cell Dev. Biol. 39, 391–408 (2023).
Yigit, B. et al. A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget 7, 26346–26360 (2016).
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H. & Riley, J. L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945–954 (2004).
Perez-Villar, J. J. et al. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol. Cell. Biol. 19, 2903–2912 (1999).
Celis-Gutierrez, J. et al. Quantitative interactomics in primary T cells provides a rationale for concomitant PD-1 and BTLA coinhibitor blockade in cancer immunotherapy. Cell Rep. 27, 3315–3330.e7 (2019).
Perkins, L. A., Larsen, I. & Perrimon, N. Corkscrew encodes a putative protein tyrosine phosphatase that functions to transduce the terminal signal from the receptor tyrosine kinase torso. Cell 70, 225–236 (1992).
Veillette, A., Latour, S. & Davidson, D. Negative regulation of immunoreceptor signaling. Annu. Rev. Immunol. 20, 669–707 (2002).
Cannons, J. L. et al. SAP regulates TH2 differentiation and PKC-θ-mediated activation of NF-κB1. Immunity 21, 693–706 (2004).
Davidson, D. et al. Genetic evidence linking SAP, the X-linked lymphoproliferative gene product, to Src-related kinase FynT in TH2 cytokine regulation. Immunity 21, 707–717 (2004).
Tang, Z. et al. CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity. Nat. Immunol. 24, 2032–2041 (2023).
Blanchard, E. L. et al. Proximity ligation assays for in situ detection of innate immune activation: focus on in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 14, 52–66 (2019).
Zhao, M. et al. Rapid in vitro generation of bona fide exhausted CD8+ T cells is accompanied by Tcf7 promotor methylation. PLoS Pathog. 16, e1008555 (2020).
Vardhana, S. A. et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat. Immunol. 21, 1022–1033 (2020).
McManus, D. T. et al. An early precursor CD8+ T cell that adapts to acute or chronic viral infection. Nature 640, 772–781 (2025).
Ruan, X. et al. Two chemotherapeutic agents expand stem-like CD62L+CD8+ T cells in antitumor immune responses. Front. Immunol. 16, 1533857 (2025).
Liu, Z. et al. Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell 41, 1852–1870 (2023).
Chu, Y. et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat. Med. 29, 1550–1562 (2023).
Oba, T., Long, M. D., Ito, K. I. & Ito, F. Clinical and immunological relevance of SLAMF6 expression in the tumor microenvironment of breast cancer and melanoma. Sci. Rep. 14, 2394 (2024).
Davidson, D. et al. The Csk-associated adaptor PAG inhibits effector T cell activation in cooperation with phosphatase PTPN22 and Dok adaptors. Cell Rep. 17, 2776–2788 (2016).
Li, B. et al. Cis interactions between CD2 and its ligands on T cells are required for T cell activation. Sci. Immunol. 7, eabn6373 (2022).
Li, B. et al. Code for ‘SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer’. Zenodo https://doi.org/10.5281/zenodo.17902239 (2026).
